Table 1

Baseline characteristics by response status at approximately 1 year

Non-responder (n=42)Responder (n=41)P value
Demographics (n (%) unless stated)
 Age at biopsy, years, mean (SD)32 (11)31 (9.6)0.455
 Sex, female39 (91)39 (89)1.000
 Race, black41 (95)38 (86)0.266
Baseline lab measures (median, IQR unless stated)
 Urine protein-to-creatinine ratio (g/g)2.7 (4.8)1.31 (3.7)0.018
 eGFR92 (76)106 (77)0.534
 Serum C3 (mg/dL), mean (SD)65 (30)71 (29)0.554
 C4, mean (SD)15 (8.6)16 (7.3)0.761
 Anti-dsDNA antibodies176 (162)119 (189)0.256
 Serum creatinine1.0 (1.3)0.90 (0.70)0.269
 White blood cell count5.8 (4.4)6.5 (6.1)0.504
 Platelets251 (123)247 (113)0.745
 Haemoglobin, mean (SD)10 (1.4)10 (1.4)0.656
 Albumin, mean (SD)2.4 (0.8)2.6 (0.6)0.149
Baseline pathology (# patients >0, median (IQR) or # of patients (%))
 Activity score38, 5 (5)35, 3 (6)0.091
 Chronicity score36, 4 (5)34, 2 (2)0.004
 Interstitial fibrosis34, 2 (1.)24, 1 (1)0.001
 Interstitial inflammation30, 1 (1)29, 1 (1)0.978
 Glomeruli42, 18 (13)41, 19 (11)0.539
 Crescents15, 0 (2)20, 0 (2)0.382
 Crescent:Glomeruli ratio15, 0 (0.2)20, 0 (0.08)0.261
 Necrosis1 (1)2 (1)0.703
 Proliferative disease, yes37 (86)32 (73)0.125
 Membranous disease, yes23 (53)20 (46)0.454
 Mesangial disease, yes3 (7)6 (14)0.484
Thrombotic microangiopathy (#, %)2 (5)1 (2)1.000
Induction medication use (n (%))
 Prednisone, yes36 (86)38 (93)0.307
 Hydroxychloroquine, yes34 (81)34 (83)0.815
 Mycophenolate/Mycophenolic acid, yes28 (67)32 (78)0.367
 Cyclophosphamide, yes14 (33)9 (22)0.361
 Rituximab, yes6 (14)1 (2.4)0.109
 Azathioprine, yes7 (17)6 (15)0.799
# immunosuppressants at baseline*
 00 (0)0 (0)
 1–212 (29)10 (24)0.403
 ≥330 (71)31 (76)
  • dsDNA, double stranded DNA; eGFR, estimated glomerular filtration rate.